[ad_1]
Takeda Pharmaceutical Co Ltd announced Tuesday that it has received approval from the United States for the acquisition of London-based Shire Plc for $ 62 billion, a step further from the Japanese pharmaceutical company toward its goal of becoming
The company said in a statement that it had received unconditional authorization from the US Federal Trade Commission.
The Tokyo-based company is still waiting for the regulatory approval of China and the European Union, among others, in addition to the approval of the shareholders of both sides to the agreement .
Managing Director Christophe Weber strives to convince investors of the benefits of the merger in terms of savings. But worries about the combined financial burden of the combined company weighed heavily on the price of Takeda's stock
Japanese checkers closed flat on Tuesday before the announcement. The stock has fallen 16% since Takeda announced late March that it was pricing an offer to buy Shire.
The pharmaceutical company expects the agreement to be finalized in the first half of 2019.
[ad_2]
Source link
